[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-ii-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-ii-lung-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100624623","precise-exercise-regimen-for-cancer-care-percc-a-pilot-study-100624623",false,"NCT07412041","Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study","PERCC","Inclusion Criteria:\n\n* Age ≥18 years at time of diagnosis; due to the rarity of the disease in those \\\u003C18 years, this age bracket will not be included.\n* Histologically diagnosed with stage II or III non-small cell lung cancer (NSCLC) and has not started lung cancer treatment.\n* Patient's treatment plan is to receive neoadjuvant therapy (defined as chemotherapy, chemotherapy and immunotherapy, or chemotherapy and radiation therapy) followed by surgical treatment. Patients will be enrolled at least three weeks prior to receiving their first neoadjuvant treatment.\n* Ability to follow directions and complete questionnaires in English and\u002For Spanish.\n* Ability to understand and the willingness to sign a written informed consent document prior to any study-related procedures.\n* Willing to travel to DFCI for necessary data collection.\n\nExclusion Criteria:\n\n* Patients who are morbidly obese (BMI\\>40 kg\u002Fm2) or Anorexic (BMI\\\u003C17 kg\u002Fm2).\n* Unstable comorbidities that contraindicate participation in exercise program compliance. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because part of this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded. Study staff will identify untreated or unmanaged conditions when screening and treating MDs must provide clearance prior to patient enrollment.\n* Patients with alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer).\n* Patients scheduled to receive single modality cancer treatment (unimodal therapy), scheduled surgery within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started.\n* Patients who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.\n* Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.",[26,27,28,29],"Stage II Lung Cancer","Lung Cancer","Non-small Cell Lung Cancer","NSCLC",[26,27,28,29],"RECRUITING","2026-08-03",{"date":34,"type":35},"2026-08-05","ACTUAL",{"date":37,"type":35},"2026-01-22",{"date":39,"type":20},"2028-03-30",{"name":41,"class":42},"Dana-Farber Cancer Institute","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100460869","avecure-flexible-microwave-ablation-probe-for-lung-nodules-100460869","NCT05281237","Avecure Flexible Microwave Ablation Probe For Lung Nodules","Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule","Inclusion Criteria:\n\n* Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.\n* Pathological proof of target nodule\u002Ftumor type and malignancy with specimen considered adequate per institutional laboratory standards\n* Target nodule\u002Ftumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively\n* Resection\u002Fsurgical candidate (lobectomy or greater)\n* Participants must be at least 22 years old and able to provide consent\n\nExclusion Criteria:\n\n* Subjects in whom flexible bronchoscopy is contraindicated\n* Target nodule \\\u003C 1.0 cm\n* Prior radiation or neo adjuvant chemotherapy of the target nodule\u002Ftumor\n* Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives\n* Pacemaker, implantable cardioverter, or another electronic implantable device\n* Patient cannot tolerate bronchoscopy\n* Patients with coagulopathy\n* Patients in other therapeutic lung cancer studies\n* Subject is pregnant or breastfeeding\n* COVID-19 positive patient at the time of procedure.","22 Years",{"count":53,"type":20},10,[23],"This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size.\n\nThis research study involves microwave ablation (MWA)",[57,58,26,59,60,27],"Stage I - II Primary Lung Cancer","Stage I Lung Cancer","Lung Cancer Stage I","Lung Cancer Stage II",[62,58,26,59,60,27],"Stage I - II primary lung cancer","2026-04-07",{"date":65,"type":35},"2026-04-08",{"date":67,"type":35},"2022-06-01",{"date":69,"type":20},"2027-06-30",{"name":71,"class":42},"Beth Israel Deaconess Medical Center"]